DDInter511 DDInter1376
Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Desvenlafaxine {u} (Compound) resembles {v} (Compound) Cyclopentolate
Desvenlafaxine {u} (Compound) binds {v} (Gene) SLC6A2
Desvenlafaxine {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Desvenlafaxine {u} (Compound) causes {v} (Side Effect) Hot flush
Desvenlafaxine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Urea
Desvenlafaxine {u} may lead to a major life threatening interaction when taken with {v} Dextromethorphan
Desvenlafaxine {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Desvenlafaxine (Compound) resembles Cyclopentolate (Compound)
Desvenlafaxine (Compound) binds SLC6A2 (Gene)
Desvenlafaxine (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Desvenlafaxine (Compound) causes Hot flush (Side Effect)
Desvenlafaxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Urea
Desvenlafaxine may lead to a major life threatening interaction when taken with Dextromethorphan
Desvenlafaxine may lead to a major life threatening interaction when taken with Methylene blue
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Desvenlafaxine may lead to a major life threatening interaction when taken with Iobenguane